3HKY

HCV NS5B polymerase genotype 1b in complex with 1,5 benzodiazepine 6

3HKY の概要

• エントリーDOI: 10.2210/pdb3hky/pdb
• 関連するPDBエントリー: 3CSO 3HKW
• 分子名称: RNA-directed RNA polymerase, (11S)-10-[(2,5-dimethyl-1,3-oxazol-4-yl)carbonyl]-11-{2-fluoro-4-[(2-methylprop-2-en-1-yl)oxy]phenyl}-3,3-dimethyl-2,3,4,5,10,11-hexahydrothiopyrano[3,2-b][1,5]benzodiazepin-6-ol 1,1-dioxide, SULFATE ION, ... (5 entities in total)
• 機能のキーワード: hepatitis c virus, 1, 5-benzodiazepine, genotype, ns5b, polymerase, biacore, replicon, transferase
• 由来する生物種: Hepatitis C virus subtype 1b
• 細胞内の位置: Core protein p21: Host endoplasmic reticulum membrane ; Single-pass membrane protein . Core protein p19: Virion . Envelope glycoprotein E1: Virion membrane ; Single-pass type I membrane protein . Envelope glycoprotein E2: Virion membrane ; Single-pass type I membrane protein . p7: Host endoplasmic reticulum membrane ; Multi-pass membrane protein . Protease NS2-3: Host endoplasmic reticulum membrane ; Multi-pass membrane protein . Serine protease NS3: Host endoplasmic reticulum membrane ; Peripheral membrane protein . Non-structural protein 4A: Host endoplasmic reticulum membrane ; Single-pass type I membrane protein . Non-structural protein 4B: Host endoplasmic reticulum membrane ; Multi-pass membrane protein . Non-structural protein 5A: Host endoplasmic reticulum membrane ; Peripheral membrane protein . RNA-directed RNA polymerase: Host endoplasmic reticulum membrane ; Single-pass type I membrane protein : O92972
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 131637.24

構造登録者

Nyanguile, O.,De Bondt, H.L. (登録日: 2009-05-26, 公開日: 2010-05-26, 最終更新日: 2023-11-01)

主引用文献

Nyanguile, O.,Devogelaere, B.,Vijgen, L.,Van den Broeck, W.,Pauwels, F.,Cummings, M.D.,De Bondt, H.L.,Vos, A.M.,Berke, J.M.,Lenz, O.,Vandercruyssen, G.,Vermeiren, K.,Mostmans, W.,Dehertogh, P.,Delouvroy, F.,Vendeville, S.,VanDyck, K.,Dockx, K.,Cleiren, E.,Raboisson, P.,Simmen, K.A.,Fanning, G.C.
1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus
J.Virol., 84:2923-2934, 2010

PubMed Abstract: The RNA-dependent RNA polymerase (NS5B) of hepatitis C virus (HCV) is an unusually attractive target for drug discovery since it contains five distinct drugable sites. The success of novel antiviral therapies will require nonnucleoside inhibitors to be active in at least patients infected with HCV of subtypes 1a and 1b. Therefore, the genotypic assessment of these agents against clinical isolates derived from genotype 1-infected patients is an important prerequisite for the selection of suitable candidates for clinical development. Here we report the 1a/1b subtype profiling of polymerase inhibitors that bind at each of the four known nonnucleoside binding sites. We show that inhibition of all of the clinical isolates tested is maintained, except for inhibitors that bind at the palm-1 binding site. Subtype coverage varies across chemotypes within this class of inhibitors, and inhibition of genotype 1a improves when hydrophobic contact with the polymerase is increased. We investigated if the polymorphism of the palm-1 binding site is the sole cause of the reduced susceptibility of subtype 1a to inhibition by 1,5-benzodiazepines by using reverse genetics, X-ray crystallography, and surface plasmon resonance studies. We showed Y415F to be a key determinant in conferring resistance on subtype 1a, with this effect being mediated through an inhibitor- and enzyme-bound water molecule. Binding studies revealed that the mechanism of subtype 1a resistance is faster dissociation of the inhibitor from the enzyme.

PubMed: 20071590
DOI: 10.1128/JVI.01980-09

実験手法

X-RAY DIFFRACTION (1.9 Å)